Skip to main content

Table 1 List of CNS diseases and current strategies targeting the disease hallmarks

From: Therapeutic nanoplatforms and delivery strategies for neurological disorders

 

Biomarker

Targeting strategy

Purpose

Examples

Refs.

GBM

MGMT methylation

Methylation-primer

Diagnosis

PCR-mMGMT

[149]

PDGFRA mutation

PDGFRS-primer

Diagnosis

qPCR, qPCR-SSCP

[150]

PDGR inhibitor

GBM treatment

Sorafenib

Matinib

Tandutinib

Dasatinib

[151]

IDH mutation

Anti-R132H-IDH1

Diagnosis

Immunohistochemistry

[152]

EGFR mutation

Anti-EGFRvIII

Diagnosis

Immunohistochemistry

[153]

EGFR inhibitor

GBM treatment

Erlotinib

Nimotuzumab

Gefitinib

Cetuximab

[151]

PD-1

PD-1 inhibitor

GBM treatment

Nivolumab

Pembrolizumab

[18]

CTLA-4

CTLA-4 inhibitor

GBM treatment

Ipilimumab

[18]

AD

Aβ oligomer

Aβ aggregation inhibitor

AD treatment

Tramiprosate

[21]

Aβ plaque

Aβ aggregation inhibitor

AD treatment

Colostrinin

[22]

Aβ PET ligand

PET imaging

CRANAD

NIAD

[154]

Tau

Tau aggregation inhibitor

AD treatment

Astemizole

Lansoprazole

[23]

PD

DAT

Dopamine

PD treatment

L-DOPA

[27]

Dopamine agonist

PD treatment

Bromocriptine

[28]

D2/D3 radioligands

SPEC imaging

PET imaging

PET imaging

123I-iodolisuride

11C-Raclopride

18F-Fallypride

[155]

Cocaine derivatives

PET imaging

PET imaging

125I-RTI-55

76Br-PE2Br

[155]

α-Synuclein

Anti-α-synuclein

Diagnosis

ELISA

[143]